A recent study shows that the genetic suppression of KV3.3 channels using antisense oligonucleotides (ASOs) can reverse the SCA13 outcomes (Zhang et al., 2021), meaning that targeting KV3.3 expression may provide a potential therapeutic approach for SCA13. This evidence concerns the gene KCNC3 and spinocerebellar ataxia type 13.